TRUENAT PLATFORM - SCI
& TECH
News: India-made TB diagnostics tech
wins acclaim at World Health Assembly
What's in the news?
●
The Truenat platform, a rapid molecular test for the diagnosis of pulmonary, extrapulmonary,
and rifampicin-resistant tuberculosis, that was developed in India, has
been hailed for its role in combating TB and as a possible component of global
healthcare solutions at the recently-held 77th World Health Assembly in Geneva.
Key takeaways:
●
At the World
Health Assembly (the decision-making body of the WHO), the Global Fund,
which collaborates with the WHO to build stronger health systems across the
globe, appreciated India’s commitment to eliminating TB by creating mass
awareness, and intensive monitoring programmes using digital technologies.
Truenat Platform:
●
It was developed by Goa-based Molbio Diagnostics, is a ground-breaking innovation in
the field of molecular diagnostics.
Features:
●
It is a real-time
quantitative micro-PCR system.
●
It is a portable,
battery-operated machine that can be deployed at labs, health centers, and even
in the field.
●
It delivers results from samples in less than an
hour and can test for over 40 diseases
including Covid-19, HCV, HBV, HIV, HPV, dengue, malaria, influenza, herpes,
typhoid, and TB.
Game-Changer in TB
Diagnostics:
●
The platform provides a rapid molecular test for
the diagnosis of pulmonary, extrapulmonary, and rifampicin-resistant
tuberculosis.
Go back to basics:
World Health Assembly:
●
It is the decision-making
body of the World Health Organization (WHO).
●
It is attended by delegations from all WHO Member
States and focuses on a specific health agenda prepared by the Executive Board.
●
The Health Assembly is held annually in Geneva, Switzerland.